65.87

2.75% -1.86

Halozyme Therapeutics Inc (HALO)

Overview News Price History Option Chain Financials Why HALO Down? Discussions Forecast

Halozyme Therapeutics Inc stock is traded at $65.87, with a volume of 2.50M. It is down -2.75% in the last 24 hours and up +8.61% over the past month. Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.

Previous Close:

$67.73

Open:

$68.11

24h Volume:

2.50M

Relative Volume:

1.54

Market Cap:

$7.56B

Revenue:

$947.36M

Net Income/Loss:

$392.47M

P/E Ratio:

21.81

EPS:

3.02

Net Cash Flow:

$392.71M

1W Performance:

+7.65%

1M Performance:

+8.61%

6M Performance:

+8.02%

1Y Performance:

+50.25%

1-Day Range:

$65.68

$69.94

1-Week Range:

$58.38

$70.50

52-Week Range:

$42.01

$70.50

Halozyme Therapeutics Inc Stock (HALO) Company Profile

Name

Halozyme Therapeutics Inc

Sector

Healthcare (1153)

Industry

Biotechnology (676)

Phone

(858) 794-8889

Address

12390 EL CAMINO REAL, SAN DIEGO, CA

Employee

350

Twitter

@halozymeinc

Next Earnings Date

2025-02-18

Latest SEC Filings

HALO's Discussions on Twitter

Compare HALO with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
HALO Halozyme Therapeutics Inc	65.87	7.56B	947.36M	392.47M	392.71M	3.02
VRTX Vertex Pharmaceuticals Inc	424.99	128.84B	11.10B	-988.90M	-1.26B	-3.92
REGN Regeneron Pharmaceuticals Inc	527.78	65.38B	14.09B	4.50B	2.96B	39.28
ARGX Argen X Se Adr	549.65	39.67B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	251.15	33.82B	2.35B	-269.70M	-75.39M	-2.09
ONC Beigene Ltd Adr	231.99	27.60B	3.81B	-644.79M	-669.77M	-6.24

Halozyme Therapeutics Inc Stock (HALO) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Oct-07-24	Downgrade	Wells Fargo	Overweight → Equal Weight
Sep-19-24	Downgrade	JP Morgan	Overweight → Neutral
Jun-07-24	Downgrade	Piper Sandler	Overweight → Neutral
Feb-29-24	Initiated	TD Cowen	Outperform
Jul-24-23	Downgrade	Goldman	Buy → Neutral
Jul-24-23	Initiated	H.C. Wainwright	Buy
May-10-23	Upgrade	Piper Sandler	Neutral → Overweight
Mar-27-23	Resumed	Berenberg	Buy
Mar-16-23	Downgrade	SVB Securities	Outperform → Market Perform
Dec-21-22	Resumed	Morgan Stanley	Overweight
Nov-28-22	Initiated	Wells Fargo	Overweight
Sep-09-22	Initiated	Morgan Stanley	Overweight
May-23-22	Initiated	SVB Leerink	Outperform
Jun-14-21	Initiated	Evercore ISI	Outperform
May-17-21	Initiated	SVB Leerink	Outperform
May-11-21	Downgrade	Piper Sandler	Overweight → Neutral
Jan-21-21	Reiterated	The Benchmark Company	Buy
Dec-17-20	Initiated	Berenberg	Buy
Sep-14-20	Resumed	JP Morgan	Overweight
Jul-01-20	Initiated	The Benchmark Company	Buy
Feb-05-20	Upgrade	Piper Sandler	Neutral → Overweight
Jan-09-20	Upgrade	BMO Capital Markets	Market Perform → Outperform
Jan-08-20	Initiated	Goldman	Buy
Nov-05-19	Upgrade	Barclays	Underweight → Equal Weight
Oct-19-18	Resumed	Piper Jaffray	Neutral
May-11-18	Downgrade	Barclays	Equal Weight → Underweight
Jan-24-18	Initiated	Goldman	Neutral
Oct-16-17	Reiterated	Piper Jaffray	Overweight
Jan-06-17	Downgrade	Citigroup	Buy → Neutral
Nov-03-16	Initiated	Deutsche Bank	Buy
Dec-04-15	Initiated	Wells Fargo	Outperform
Nov-18-15	Initiated	Citigroup	Buy
Sep-22-15	Initiated	Barclays	Overweight
Jun-22-15	Reiterated	JP Morgan	Overweight
Mar-03-15	Reiterated	UBS	Buy
Feb-18-15	Reiterated	MLV & Co	Buy
Jan-08-15	Reiterated	MLV & Co	Buy

View All

Halozyme Therapeutics Inc Stock (HALO) Latest News

May 09, 2025

Halozyme Therapeutics (HALO) is a Great Momentum Stock: Should You Buy? - Yahoo Finance

May 09, 2025